Drug Profile


Alternative Names: Cannabidiol/delta-9-tetrahydrocannabivarin - GW Pharmaceuticals; GW42004/GW42003; Tetrahydrocannabivarol-9/cannabidiol; THCV/CBD

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GW Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Dyslipidaemias; Metabolic disorders

Highest Development Phases

  • No development reported Dyslipidaemias; Type 2 diabetes mellitus
  • Discontinued Metabolic syndrome; Obesity

Most Recent Events

  • 17 Feb 2016 No development reported - Phase-II for Dyslipidaemias in United Kingdom (PO)
  • 17 Feb 2016 No development reported - Phase-II for Type-2 diabetes mellitus in United Kingdom (PO)
  • 03 Sep 2015 Phase-II development is still ongoing for Type-2 diabetes mellitus and Dyslipidaemias
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top